Tmunity Therapeutics

39 articles about Tmunity Therapeutics

• 

  FDA Puts 2seventy bio’s CAR-T Trial on Formal Hold After Patient Death

  8/14/2023

  The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.

• Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer

  12/20/2022

  Kite today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies.

• 

  Astellas, Tmunity, Underscore Rocky Terrain of CAR-T and Gene Therapies

  4/25/2022

  Patient deaths associated with Astellas Pharma’s gene therapy candidate underscore the risks of developing potential one-and-done treatment options for serious diseases.
• 

  FDA Formalizes Celyad CAR-T Trial Hold while Risks Evaluated

  3/2/2022

  Belgium-based Celyad Oncology voluntarily paused a clinical trial with Merck after two deaths. Getting CAR T therapies to work in solid tumors has proven to be a difficult challenge.
• 

  CytoImmune is Cell Therapy Veteran Christina Coughlin's Next Act

  11/10/2021

  Cell therapy veteran Christina Coughlin is taking over the reins of the privately-held company developing natural killer immune cells to battle cancer.
• 

  CAR-T Pioneer Carl June Will Lend Wisdom to Bioheng Biotech

  10/19/2021

  June really broke out in 2012 when he saved the life of Emily Whitehead, a child suffering from relapsed acute lymphoblastic leukemia (ALL), with CD19 CAR-T.

• Tmunity Therapeutics Announces Expansion of T Cell Engineered Therapy Collaboration

  2/9/2021

  Continued access to leading innovation from Penn’s Center for Cellular Immunotherapies (CCI) Expanded rights to Penn cell manufacturing and platform technologies Exclusive rights to an additional CAR T-cell therapy product for multiple solid tumors

• Tmunity Announces Appointment of Jeffrey Leiden M.D., Ph.D. as Chairman of the Board of Directors

  1/25/2021

  Tmunity Therapeutics, Inc., a clinical-stage biotherapeutics company specifically designed to deliver on the bold promise to ‘uncancer the world’ by creating the best T cell medicines for solid tumor patients, today announced the appointment of Jeffrey Leiden, M.D., Ph.D., as Non-Executive Chairman of its Board of Directors.

• Tmunity to Present at the 2020 RBC Capital Markets Healthcare Private Company Conference

  12/9/2020

  Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today announced that President & CEO Usman “Oz” Azam will participate in a Fireside Chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Tuesday, December 15, 2020 at 11:20 am Eastern Time. To access a liv

• Tmunity to Present at Upcoming Investor Conferences - Nov 05, 2020

  11/5/2020

  Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, announced that President & CEO Usman “Oz” Azam will present at two upcoming virtual investor conferences in November.​

• Tmunity to Present at Upcoming Investor Conferences - Sep 29, 2020

  9/29/2020

  Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, announced that President & CEO Usman “Oz” Azam is scheduled to present at two upcoming virtual investor conferences.​

• Tmunity Announces Additional Senior Leadership Appointments

  9/8/2020

  Dr. Vijay Reddy and Simona King, CPA, MBA to Join Executive Team as Chief Research and Development Officer and Chief Financial Officer.

• Tmunity to Present at Upcoming Investor Conferences

  2/19/2020

  Feb. 19, 2020 12:00 UTC PHILADELPHIA--( BUSINESS WIRE )-- Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today announced that management is scheduled to present at two upcoming investor conferences. Cowen 40th Annual Health Care Conference Monday, March 2, 2020 1:30 PM ET Boston, MA Oppenheimer 30th Annual Healthcare Conferen

• Tmunity Announces First Patient Dosed in Phase 1 Clinical Trial with CART-TnMUC1

  1/15/2020

  Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, today announced that it has dosed the first patient in its Phase 1 CART-TnMUC1-01 clinical trial with the Tn/STn glycoform of mucin 1 (TnMUC1) chimeric antigen receptor T-cell (CAR-T) therapy in patients with TnMUC1-positive advanced cancers.

• Tmunity to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/9/2020

  Tmunity Therapeutics, Inc. announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:30 pm Pacific Time at the Westin St. Francis Hotel in San Francisco.

• Tmunity and Oncora Medical Partner to Advance the Use of Real-World Data to Accelerate the Availability of CAR-T Therapies for Cancer Patients

  11/4/2019

  Tmunity will use Oncora Medical’s proprietary analytical tools to access real world data and innovate clinical trial design

• Tmunity Raises $75 Million in Series B Financing to Advance Next-Generation T-Cell Therapies

  10/31/2019

  Series B investors include venture capital, industry, academia, patient advocacy groups and philanthropy

• Tmunity Announces Exclusive License and Research Collaboration with Children’s Hospital of Philadelphia to Advance GPC2 CAR-T Cell Therapy for Neuroblastoma

  10/1/2019

  Tmunity Therapeutics, Inc. announced it has entered into an exclusive license and research collaboration agreement with Children’s Hospital of Philadelphia to advance a glypican 2 chimeric antigen receptor T-cell therapy for the treatment of neuroblastoma, a rare cancer that affects the developing nervous system.

• Tmunity Announces Presentation at the Cantor Fitzgerald 2019 Global Healthcare Conference

  9/27/2019

  Tmunity Therapeutics, Inc. announced that Christina Coughlin, MD, PhD, Executive Vice President and Chief Medical Officer, and members of the management team plan to participate at the Cantor Fitzgerald 2019 Global Healthcare Conference in New York City on October 3, 2019.

• Tmunity Announces Participation at Upcoming Investor Conferences

  8/23/2019

  Tmunity Therapeutics, Inc. announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at two investor conferences in September and October 2019.